Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Refractive Surgery/Vision Correction > SUPRACOR TENEO 317 LASIK for Presbyopia Shows Efficacy and Stability
  • Refractive Surgery/Vision Correction

SUPRACOR TENEO 317 LASIK for Presbyopia Shows Efficacy and Stability

Ophthalmology 360
SUPRACOR TENEO 317 LASIK for Presbyopia Shows Efficacy and Stability

A new study has found that LASIK performed with the TECNOLAS TENEO excimer laser (Bausch & Lomb Technolas, Munich, Germany) showed efficacy at 24 months. Specifically, TECNOLAS Perfect Vision GmbH TENEO 317 software version 1.25 with the PROSCAN platform for the distance dominant eye and the SUPRACOR mild platform for the near dominant eye was used.

The retrospective, observational, and longitudinal study included 80 eyes from 40 patients who underwent hyperopic and presbyopic LASIK. Follow-up was 24 months.

Results showed that 93% of eyes achieved 20/20 or better binocular uncorrected distance visual acuity (UDVA); 90% achieved J1.5 or better binocular uncorrected near visual acuity. Postoperative UDVA was 0.00 ± 0.04 (20/19.97) for the dominant eye and 0.14 ± 0.05 (20/27.65) for the non-dominant eye. Postoperative uncorrected near visual acuity was 0.51 ± 0.17 (J9) for the dominant eye and 0.09 ± 0.06 (J1.5) for the non-dominant eye; 2.5% of non-dominant eyes lost two lines of corrected distance visual acuity. Between months 3 and 24, a slight regression occurred. A change of +0.22 D was reported for the nondominant eye and a change of +0.39 D was reported for the dominant eye.

Overall, PROSCAN surgery in the dominant eye and SUPRACOR surgery in the non-dominant eye using the TENEO 317 algorithm resulted in safety, efficacy, and stability at 24 months.

Reference:

Sánchez-González JM, Alonso-Aliste F, Amián-Cordero J, Sánchez-González MC, De-Hita-Cantalejo C. Refractive and visual outcomes of SUPRACOR TENEO 317 LASIK for presbyopia in hyperopic eyes: 24-month follow-up. J Refract Surg. 2019;35(9):591–598. doi: 10.3928/1081597X-20190815-01.

Share

Related Content

  • Refractive Surgery/Vision Correction

VISUMAX 800 lenticule extraction linked to high satisfaction and spectacle independence

  • Cataract

Spotlight on TECNIS Odyssey™

  • Cataract

IOL exchange shows highest success for dissatisfaction after presbyopia-correcting lens surgery

  • Conference Roundup

OmniVu modular shape-changing IOL offers stable refraction and sustained improvement in near vision

  • Conference Roundup

How depth of field IOL technologies can provide tolerance to refractive error

  • Refractive Surgery/Vision Correction

First-in-human study underway for non-invasive vision correction technology

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon